share_log

bluebird bio | 10-K: FY2023 Annual Report

bluebird bio | 10-K: FY2023 Annual Report

bluebird bio | 10-K:2023财年年报
美股SEC公告 ·  09/13 16:33

Moomoo AI 已提取核心信息

bluebird bio, a biotechnology company specializing in gene therapies, reported a net loss of $211.9 million for the year ended December 31, 2023, with an accumulated deficit of $4.3 billion. Despite this, the company saw an increase in product revenue, netting $29.1 million, primarily from U.S. sales of ZYNTEGLO and SKYSONA, and the recent FDA approval of LYFGENIA in December 2023. The cost of product revenue rose to $33.5 million, attributed to increased product sales. Selling, general and administrative expenses also increased by $25.2 million due to higher IT, facility-related costs, and commercial activities for their gene therapies. Research and development expenses decreased by $32.8 million, reflecting a shift of certain expenses to inventory and cost of product revenue following commercialization. The company sold two Priority Review...Show More
bluebird bio, a biotechnology company specializing in gene therapies, reported a net loss of $211.9 million for the year ended December 31, 2023, with an accumulated deficit of $4.3 billion. Despite this, the company saw an increase in product revenue, netting $29.1 million, primarily from U.S. sales of ZYNTEGLO and SKYSONA, and the recent FDA approval of LYFGENIA in December 2023. The cost of product revenue rose to $33.5 million, attributed to increased product sales. Selling, general and administrative expenses also increased by $25.2 million due to higher IT, facility-related costs, and commercial activities for their gene therapies. Research and development expenses decreased by $32.8 million, reflecting a shift of certain expenses to inventory and cost of product revenue following commercialization. The company sold two Priority Review Vouchers in 2022 and 2023, with net proceeds of $102.0 million and $92.9 million, respectively. As of December 31, 2023, bluebird bio had cash and cash equivalents of approximately $221.8 million and expects this to fund operations into the first quarter of 2025. The company's future plans include continued commercialization of ZYNTEGLO, SKYSONA, and LYFGENIA in the U.S., scaling manufacturing capabilities, and conducting clinical studies.
bluebird bio是一家专门从事基因疗法的生物技术公司,报告了2023年12月31日结束的一年净亏损21,190万美元,累积亏损43亿美元。尽管如此,该公司的产品收入增加,净值达到2,910万美元,主要来自于美国ZYNTEGLO和SKYSONA的销售以及LYFGENIA在2023年12月获得美国食品和药物管理局(FDA)的批准。产品收入的成本上升到了3,350万美元,这归因于产品销售的增加。由于IT、设施相关成本和基因疗法的商业活动增加,销售、一般和行政费用也增加了2,520万美元。研发费用减少了3,280万美元,反映了某些费用在商业化后转移到库存和产品收入成本。该公司在2022年和20...展开全部
bluebird bio是一家专门从事基因疗法的生物技术公司,报告了2023年12月31日结束的一年净亏损21,190万美元,累积亏损43亿美元。尽管如此,该公司的产品收入增加,净值达到2,910万美元,主要来自于美国ZYNTEGLO和SKYSONA的销售以及LYFGENIA在2023年12月获得美国食品和药物管理局(FDA)的批准。产品收入的成本上升到了3,350万美元,这归因于产品销售的增加。由于IT、设施相关成本和基因疗法的商业活动增加,销售、一般和行政费用也增加了2,520万美元。研发费用减少了3,280万美元,反映了某些费用在商业化后转移到库存和产品收入成本。该公司在2022年和2023年售出了两张优先审核券,净收益分别为1,0200万美元和9290万美元。截至2023年12月31日,bluebird bio的现金及现金等价物约为2,2180万美元,预计可以支持公司运营至2025年第一季度。该公司的未来计划包括继续在美国推广ZYNTEGLO、SKYSONA和LYFGENIA,扩大制造能力并进行临床研究。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息